

MARKSANS PHARMA LIMITEDRegd. Office: 11th Floor, Lotus Business Park, Off. New Link Road, Andheri (West), Mumbai-400053
AUDITED STANDALONE FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2012

(₹ in Lakhs)

PART 1

		3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Current Year ended	Previous Year ended
		31.03.12	31.12.2011	31.3.2011	31.03.2012	31.03.2011
Sr. No.	PARTICULARS	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(AUDITED)	(AUDITED)
1	Income					
a)	Net Sales/ Income from Operations (Net of excise duty)	4,040.98	3,117.23	3,326.47	15,459.13	15,469.77
b)	Other Operating Income	117.46	24.74	100.07	195.41	168.64
	Total Income from operations (net)	4,158.44	3,141.97	3,426.54	15,654.54	15,638.41
2	Expenses					
a)	Cost of Material Consumed	637.86	2,265.87	1,280.31	6,050.10	4,351.85
b)	Purchase of Stock - in- trade	328.02	400.19	876.20	1,692.58	6,376.44
c)	Changes in Inventories of finished goods , work-in -progress and stock- in- trade	1,036.57	(1.38)	5.48	1,033.16	3.55
d)	Employee benefits expense	382.48	350.20	322.49	1,354.89	1,137.68
e)	Depreciation and amortisation expense	(12.08)	86.27	981.69	1,798.12	1,464.39
f)	Other expenses	13,432.62	5,787.26	12,870.28	20,827.62	14,017.77
	Total Expenses	15,805.47	8,888.41	16,336.45	32,756.47	27,351.68
3	Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	(11,647.03)	(5,746.44)	(12,909.91)	(17,101.93)	(11,713.27)
4	Other Income	-	-	-	-	-
5	Profit/(Loss) from Ordinary activities before finance costs and exceptional items(3+4)	(11,647.03)	(5,746.44)	(12,909.91)	(17,101.93)	(11,713.27)
6	Finance cost	341.10	307.67	306.76	1,188.36	1,559.34
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items(5-6)	(11,988.13)	(6,054.11)	(13,216.67)	(18,290.29)	(13,272.61)
8	Exceptional items	-	-	-	-	-
9	Profit/(Loss) from Ordinary activities before Tax (7-8)	(11,988.13)	(6,054.11)	(13,216.67)	(18,290.29)	(13,272.61)
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Year)	(183.69)	-	484.63	(183.69)	484.63
11	Net Profit/(Loss) from Ordinary activities after tax(9-10)	(11,804.44)	(6,054.11)	(13,701.30)	(18,106.60)	(13,757.24)
12	Less: Extraordinary Item-(Loss)/Profit on sale of division/Fixed assets	-	-	(85.29)	-	(8,021.68)
13	Net Profit/ (Loss) for the period (11-12)	(11,804.44)	(6,054.11)	(13,786.59)	(18,106.60)	(21,778.92)
14	Paid up Equity Share Capital (Face Value Re.1 each)	3,678.07	3,678.07	3,678.07	3,678.07	3,678.07
15	Reserve Excluding Revaluation Reserve as per Balance Sheet of Previous Accounting year	-	-	-	9,428.22	6,031.23
16	a) Earnings Per Share (before extraordinary items.Rs.)- Basic	(3.21)	(1.65)	(3.73)	(4.92)	(3.74)
	Diluted	(3.06)	(1.57)	(3.73)	(4.70)	(3.74)
	b) Earnings Per Share(after Extraordinary items- Rs.)- Basic	(3.21)	(1.65)	(3.75)	(4.92)	(5.92)
	Diluted	(3.06)	(1.57)	(3.75)	(4.70)	(5.92)

PART 2**A PARTICULARS OF SHAREHOLDING**

1	Public Shareholding:					
	- Number of Shares	189,824,114	189,824,114	189,823,694	189,824,114	189,823,694
	- Percentage of Holding	51.61%	51.61%	51.61%	51.61%	51.61%
2	Promoters and Promoter group Shareholdings	177,983,090	177,983,090	177,983,510	177,983,090	177,983,510
a)	Pledged/Encumbered					
	- Number of Shares	NIL	NIL	NIL	NIL	NIL
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	N.A	N.A	N.A	N.A	N.A
	- Percentage of Holding (as a % of the total share capital of the Company)	N.A	N.A	N.A	N.A	N.A
b)	Non-encumbered					
	- Number of Shares	177,983,090	177,983,090	177,983,510	177,983,090	177,983,510
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	100%	100%	100%	100%	100%
	- Percentage of Holding (as a % of the total share capital of the Company)	48.39%	48.39%	48.39%	48.39%	48.39%

B INVESTOR COMPLAINTS

3 months ended

	31.03.12
Pending at the beginning of the quarter	Nil
Received during the quarter	Nil
Disposed of during the quarter	-
Remaining unresolved at the end of the quarter	-




Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 29.05.2012.
- 2 As per the audited Balance Sheet as at 31st March, 2011, the Company's Net Worth had been completely eroded. Therefore, as required under Section 15 (1) of the Sick Industrial Companies (Special Provisions) Act, 1985, the company has made a reference to the Board for Industrial and Financial Reconstruction (BIFR) for measures to be determined with respect to the company. Accordingly, the company is registered with the BIFR.
- 3 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- 4 The figure for the quarter ended March 31, 2012 are the balancing figures between audited figures in respect of the full financial year ended March 31, 2012 and the unaudited published year to date figures up to December 31, 2011 being the date of the end of the third quarter of the financial year.
- 5 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.
- 6 Statement of Assets and Liabilities:

		₹ in Lakhs	
		As at March 31 (Audited)	
		2012	2011
A	EQUITY AND LIABILITIES		
	Shareholders' funds		
	(a) Share capital	5,028.07	5,028.07
	(b) Reserves and surplus	(23,951.58)	(9,241.98)
	(c) Money received against share warrants	115.66	-
	Sub-total-Shareholders' funds	(18,807.85)	(4,213.88)
	Non-current liabilities		
	(a) Long-term borrowings	1,520.14	1,900.49
	(b) Deferred tax liabilities (Net)	1,258.69	1,496.14
	Sub-total - Non-current liabilities	2,778.83	3,396.63
3	Current liabilities		
	(a) Short-term borrowings	7,718.33	8,433.29
	(b) Trade payables	2,947.85	2,997.73
	(c) Other current liabilities	29,443.49	29,850.57
	(d) Short-term provisions	512.12	209.65
	Sub-total - Current liabilities	40,621.79	41,491.24
	TOTAL-EQUITY AND LIABILITIES	24,592.77	40,673.99
B	ASSETS		
	Non-current assets		
	(a) Fixed assets	7,865.89	18,490.05
	(b) Non-current investments	2,351.46	6,761.64
	(c) Long-term loans and advances	395.09	370.09
	Sub-total - Non-current assets	10,412.24	25,621.78
	Current assets		
	(a) Inventories	4,024.70	4,001.25
	(b) Trade receivables	7,418.94	7,217.45
	(c) Cash and cash equivalents	1,758.50	2,623.78
(d) Short-term loans and advances	978.39	1,208.42	
(e) Other current assets- Miscellaneous expenditure	-	1.31	
Sub-total - Current assets	14,180.53	15,062.21	
	TOTAL ASSETS	24,592.77	40,673.99

For MARKSANS PHARMA LIMITED



MARK SALDANHA
Managing Director.


Place: Mumbai.
Date: 29.05.2012
Visit us at www.marksanspharma.com



N. K. MITTAL & ASSOCIATES

CHARTERED ACCOUNTANTS

5/5

817, Bldg. No. 3, Navjivan Commercial Premises Co.-op. Soc., Lamington Rd., Mumbai Central (E), Mumbai - 400 008.
Tel : 2309 6121 • Mob. : 98926 40589 • E-mail : ca_mittal@rediffmail.com • nkmittalandassociates@gmail.com


N. K. Mittal

B.Com, FCA, LLB, EMBA

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For N. K. MITTAL & ASSOCIATES.
Chartered Accountants




(N. K. MITTAL)
(PROPRIETOR)
(M. NO. 46785)

Place: Mumbai

Date: 29th May, 2012